College of Food Science and Engineering, Ocean University of China, 5 Yushan Road, Qingdao, 266003, Shandong, China.
Division of Analytical Chemistry, Office of Regulatory Science, Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, College Park, MD, 20740, USA.
J Nanobiotechnology. 2018 Nov 1;16(1):86. doi: 10.1186/s12951-018-0415-5.
Gold nanoparticles (AuNPs) are attracting interest as potential therapeutic agents to treat inflammatory diseases, but their anti-inflammatory mechanism of action is not clear yet. In addition, the effect of orally administered AuNPs on gut microbiota has been overlooked so far. Here, we evaluated the therapeutic and gut microbiota-modulating effects, as well as the anti-inflammatory paradigm, of AuNPs with three different coatings and five difference sizes in experimental mouse colitis and RAW264.7 macrophages.
Citrate- and polyvinylpyrrolidone (PVP)-stabilized 5-nm AuNPs (Au-5 nm/Citrate and Au-5 nm/PVP) and tannic acid (TA)-stabilized 5-, 10-, 15-, 30- and 60-nm AuNPs were intragastrically administered to C57BL/6 mice daily for 8 days during and after 5-day dextran sodium sulfate exposure. Clinical signs and colon histopathology revealed more marked anti-colitis effects by oral administration of Au-5 nm/Citrate and Au-5 nm/PVP, when compared to TA-stabilized AuNPs. Based on colonic myeloperoxidase activity, colonic and peripheral levels of interleukin-6 and tumor necrosis factor-α, and peripheral counts of leukocyte and lymphocyte, Au-5 nm/Citrate and Au-5 nm/PVP attenuated colonic and systemic inflammation more effectively than TA-stabilized AuNPs. High-throughput sequencing of fecal 16S rRNA indicated that AuNPs could induce gut dysbiosis in mice by decreasing the α-diversity, the Firmicutes/Bacteroidetes ratio, certain short-chain fatty acid-producing bacteria and Lactobacillus. Based on in vitro studies using RAW264.7 cells and electron spin resonance oximetry, AuNPs inhibited lipopolysaccharide (LPS)-triggered inducible nitric oxide (NO) synthase expression and NO production via reduction of Toll-like receptor 4 (TLR4), and attenuated LPS-induced nuclear factor kappa beta activation and proinflammatory cytokine production via both TLR4 reduction and catalytic detoxification of peroxynitrite and hydrogen peroxide.
AuNPs have promising potential as anti-inflammatory agents; however, their therapeutic applications via the oral route may have a negative impact on the gut microbiota.
金纳米粒子(AuNPs)作为治疗炎症性疾病的潜在治疗剂引起了人们的兴趣,但它们的抗炎作用机制尚不清楚。此外,目前还忽视了口服给予 AuNPs 对肠道微生物群的影响。在这里,我们评估了三种不同涂层和五种不同尺寸的 AuNPs 在实验性小鼠结肠炎和 RAW264.7 巨噬细胞中的治疗和调节肠道微生物群以及抗炎作用模式。
柠檬酸和聚乙烯吡咯烷酮(PVP)稳定的 5nm AuNPs(Au-5nm/Citrate 和 Au-5nm/PVP)和单宁酸(TA)稳定的 5nm、10nm、15nm、30nm 和 60nm AuNPs 在葡聚糖硫酸钠暴露的 5 天期间和之后,每天通过胃内给予 C57BL/6 小鼠 8 天。临床症状和结肠组织病理学显示,与 TA 稳定的 AuNPs 相比,口服 Au-5nm/Citrate 和 Au-5nm/PVP 可更显著地减轻结肠炎。根据结肠髓过氧化物酶活性、结肠和外周白细胞介素-6 和肿瘤坏死因子-α水平以及外周白细胞和淋巴细胞计数,Au-5nm/Citrate 和 Au-5nm/PVP 比 TA 稳定的 AuNPs 更有效地减轻结肠和全身炎症。粪便 16S rRNA 的高通量测序表明,AuNPs 通过降低 α-多样性、厚壁菌门/拟杆菌门比值、某些产生短链脂肪酸的细菌和乳杆菌,可诱导小鼠肠道菌群失调。基于 RAW264.7 细胞和电子自旋共振血氧测定的体外研究表明,AuNPs 通过降低 Toll 样受体 4(TLR4)来抑制脂多糖(LPS)触发的诱导型一氧化氮合酶表达和一氧化氮产生,并通过 TLR4 降低和过氧亚硝酸根和过氧化氢的催化解毒作用来减弱 LPS 诱导的核因子 kappa beta 激活和促炎细胞因子产生。
AuNPs 作为抗炎剂具有很大的应用潜力;然而,它们通过口服途径的治疗应用可能对肠道微生物群产生负面影响。